Last updated: May 31, 2026
VANCOCIN HYDROCHLORIDE suppliers: who manufactures vancomycin hydrochloride (API and finished drug) and what to check in sourcing
Vancomycin hydrochloride supply is dominated by a small set of large global sterile-injectable manufacturers for the finished product, with additional contract manufacturers producing vancomycin bulk drug substance (API) and sterile vial fills under GMP. The practical sourcing map is typically split into: (1) finished drug product suppliers (US labelers/contract sterilizers) and (2) API suppliers (vancomycin hydrochloride fermentation and crystallization producers), plus (3) packaging and distribution channel partners.
What to look for when qualifying suppliers
- Finished drug product: NDA/ANDA labeler on the carton and FDA application holder, plus cGMP status for sterile manufacturing, aseptic fill-finish, and quality system for potency, endotoxin, sterility, and impurities.
- API: manufacturer name on the DMF letter (if applicable) and ability to supply vancomycin hydrochloride to USP specifications, including impurity profile, water content, and microbial limits.
- Supply continuity: whether the supplier can dual-source across plants for lead-time stability during shortages.
Which companies supply VANCOCIN HYDROCHLORIDE (vancomycin hydrochloride) finished product in the US?
Featured snippet answer: The US market for vancomycin hydrochloride sterile injection is primarily supplied by major brand and generic sterile-injectable manufacturers and their contract manufacturing partners; qualification should be anchored to the US FDA labeler listed for the specific NDC strength and dosage form.
Key sourcing pattern: labeler and NDC-specific manufacturing
Vancomycin hydrochloride is typically marketed as sterile injection in multiple strengths (commonly 500 mg and 1 g vials, depending on NDC). Supplier due diligence should be NDC-specific because the labeler may use different fill-finish and packaging sites across lots.
Finished product supplier qualification checklist
- Confirm labeler of record for the NDC.
- Verify sterile manufacturing site (aseptic fill-finish) used for that NDC/lot range.
- Check for FDA inspection history and any recent warning letters tied to the relevant facility.
- Require lot-level certificates: potency, assay, endotoxin, sterility, and particulate matter.
Who manufactures vancomycin hydrochloride API (bulk drug substance)
Featured snippet answer: Vancomycin hydrochloride API is generally manufactured by specialized fermentation and purification plants that produce vancomycin from fermentation cultures followed by downstream purification and salt formation.
API manufacturing bottlenecks
Vancomycin is a complex fermentation product. Supplier performance is driven by:
- fermentation yield consistency,
- downstream purification capacity,
- validated impurity controls (including related substances),
- scale-up reproducibility for crystallization to the hydrochloride salt.
API supplier qualification checklist
- Provide DMF or equivalent regulatory dossier support for API (where applicable).
- Demonstrate validated impurity limits and batch-to-batch consistency.
- Confirm GMP for API production and quality control release testing.
What suppliers support vancomycin hydrochloride sterile injection contract manufacturing (CMO/CDMO)?
Featured snippet answer: Many suppliers operate as CMOs/CDMOs for sterile injectables, performing aseptic fill-finish under client labeler arrangements, often with shared sterile capacity and multiple packaging configurations.
How to map CMO/CDMO capability
- Validate sterile fill-finish capacity for vial formats and container closure systems used for vancomycin.
- Confirm compatibility of the fill process with vancomycin hydrochloride solution concentration and pH control.
- Assess stability program ownership (or transfer) for the specific formulation and container configuration.
How do API and finished product supplier choices affect price and availability for vancomycin hydrochloride?
Featured snippet answer: Price and availability track more to API fermentation and purification throughput and sterile fill-finish capacity than to distributor inventory alone, because vancomycin shortages typically stem from upstream API or downstream sterile bottlenecks.
Operational impacts
- Longer lead times often correlate with API plant cycles or crystallization steps.
- Sterile fill-finish constraints can cause late-stage lot delays even when API is available.
What delivery and packaging formats do VANCOCIN HYDROCHLORIDE suppliers offer?
Featured snippet answer: Vancomycin hydrochloride is supplied primarily as sterile vials in single-use formats, with pack configurations varying by NDC and distribution contract.
Packaging considerations for procurement
- vial size and strength matching your clinical protocol,
- container closure (rubber stopper and seal system),
- labeling language and NDC format,
- chain-of-custody and temperature excursion controls during storage and shipment.
What are the key regulatory sourcing checks for VANCOCIN HYDROCHLORIDE? (FDA, DMF, inspections)
Featured snippet answer: Regulatory sourcing hinges on confirming that the finished product and any API used are produced under GMP at approved facilities and match the regulatory filing for that specific product.
FDA-related checks procurement teams typically run
- NDC labeler and manufacturing site mapping to the FDA application.
- DMF availability for the API and alignment of the API supplier to the filed manufacturing process.
- Facility inspection status, including any data relevant to sterility assurance and aseptic processing controls.
How should procurement evaluate alternative suppliers for vancomycin hydrochloride during shortages?
Featured snippet answer: Prioritize suppliers with validated alternate sites for API and/or aseptic fill-finish, plus robust lot release and regulatory traceability for the exact NDC.
Practical evaluation framework
- Time to qualify: API-to-finished product linkage and regulatory bridge documentation.
- Quality systems: sterility assurance, endotoxin controls, and change control maturity.
- Supply resiliency: multi-plant operations and ability to meet surge demand.
What generic entry risks affect VANCOCIN HYDROCHLORIDE sourcing?
Featured snippet answer: The largest sourcing risk is not only legal generic entry but also the operational risk of maintaining sterile injectable manufacturing throughput and consistent impurity profiles when moving between API sources.
Risk areas tied to supplier substitution
- differences in API impurity profiles and how they are controlled in the finished product,
- differences in fill-finish hold times and sterility assurance validation,
- labeling/packaging changes that trigger distribution delays.
Key Takeaways
- Vancomycin hydrochloride sourcing splits into API producers and sterile injection finished product manufacturers; both layers matter for availability.
- Supplier selection should be NDC-specific for finished product and process-specific for API.
- Shortages commonly reflect upstream API throughput and downstream aseptic fill-finish constraints, so qualifying alternate manufacturing sites is central to continuity.
- Regulatory sourcing is anchored to FDA labeler-of-record, manufacturing sites, and API dossier alignment (DMF where applicable).
FAQs
1) What NDC-level supplier mapping matters most for vancomycin hydrochloride?
The manufacturing site and labeler-of-record tied to the specific NDC and strength.
2) Are vancomycin hydrochloride API suppliers interchangeable without qualification?
Not without lot-level release alignment and regulatory/quality bridge documentation; impurity and process consistency drive finished product acceptance.
3) What documentation should a vancomycin supplier provide for sterile injection release?
Lot COA covering potency/assay, endotoxin, sterility, particulate matter (as applicable), and impurity profile per specification.
4) How do I screen a new vancomycin hydrochloride supplier for GMP readiness?
Verify sterile fill-finish GMP readiness for finished product or GMP for API fermentation and purification, plus change-control and stability program evidence.
5) What factors most influence lead times for vancomycin hydrochloride?
API fermentation/purification capacity and bottlenecks in sterile aseptic fill-finish and vial/closure packaging.
References (APA)
- FDA. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
- FDA. (n.d.). Drug products list (DPL) and prescribing information resources. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). DMF information and guidance. https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs
